查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014305

细胞培养基市场：依产品类型、细胞类型、形态、应用和最终用户划分－2026-2032年全球市场预测

Cell Culture Media Market by Product Type, Cell Type, Form, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，细胞培养基市场价值将达到 17.9 亿美元，到 2026 年将成长到 20 亿美元，到 2032 年将达到 45.8 亿美元，复合年增长率为 14.28%。

主要市场统计数据
基准年 2025 17.9亿美元
预计年份：2026年 20亿美元
预测年份 2032 45.8亿美元
复合年增长率 (%) 14.28%

全面介绍为什么细胞培养基的品质、供应连续性和配方创新是现代生命科学企业的关键因素。

细胞培养基是众多生命科学应用的基础，在科研和生产环境中支持细胞增殖、分化、生产力和存活率。培养基的组成、无菌性和性能特征直接影响实验的可重复性、生物製程产量以及细胞治疗方法的临床应用成功率。鑑于其核心作用，从学术研究机构到大型生物製药公司，各组织都将培养基的选择、验证和持续供应视为至关重要的营运要务。

配方技术、分析技术、一次性生物生物製程的进步，以及对永续性的日益重视，正在重新定义细胞培养基与供应商的关係和运作模式。

近年来，研发和生产流程中涌现出许多变革性变化，重塑了企业构思、采购和应用细胞培养基的方式。配方科学的进步加速了化学成分明确和无血清培养基的普及应用，这些培养基不仅降低了变异性和监管风险，也使细胞行为更加可预测。同时，分析技术的进步，例如高解析度代谢体学和即时监测，使得对培养基性能进行更深入的分析，并能根据特定细胞类型和製程阶段定製配方成为可能。

考虑如何应对关税造成的供应链摩擦，以及影响采购韧性和供应商选择实践的策略供应基地迁移问题。

主要贸易路线上的政策变化和关税调整正为全球生命科学供应链带来巨大摩擦，迫使製造商和采购团队重新评估筹资策略、成本结构和库存缓衝。关税导致投入成本上升，促使企业更加关注原材料来源，并加快对更靠近製造地的替代供应商进行认证的步伐。此外，企业也正在审查合约条款和物流系统，以降低跨境运输带来的高昂收货成本。

我们透过提供整合的细分观点支援策略决策，该视角将产品配方、细胞培养要求、外形规格、使用案例和最终用户期望联繫起来。

有效的市场区隔提供了必要的分析观点，可以将配方科学和操作要求转化为采购和开发决策。基于产品类型，市场被分为含血清培养基和无血清培养基，这一区分会影响批次间差异、监管文件以及培养基在临床应用中的适用性等方面的考虑。基于细胞类型，市场被分为哺乳动物细胞培养基、微生物和昆虫细胞培养基以及植物细胞培养基，这反映了不同宿主系统多样化的生化需求和製程限制。基于形态，市场被分为液体培养基和粉末培养基，这会影响储存、运输和现场製备方法，也可能影响製程放大所需的前置作业时间。基于应用，市场在生物製程和生产、药物发现和测试、研发以及组织工程和再生医学等领域进行分析，揭示了性能要求如何从高通量柔软性转向临床级可重复性。按最终用户划分，对学术和研究机构、受託研究机构(CRO) 以及製药和生物技术公司进行了市场分析，重点分析了购买力、品质体係以及对技术支援和定制的期望方面的差异。

区域创新中心、监管环境和製造地如何影响全球生命科学领域的采购方式和供应商关係？

区域趋势塑造了营运重点和监管预期，进而影响细胞培养基的采购和开发。美洲地区学术机构、创新生物技术公司和大规模合约研发生产机构 (CDMO) 高度集中，对高性能、受监管的培养基和严谨的技术支援有着强劲的需求。该地区还拥有完善的物流网络，能够实现快速分销，同时合规文件和品管体係也至关重要。

深入了解科学专业知识、服务导向模式和营运可靠性如何创造竞争优势，并在培养基供应领域促进长期伙伴关係。

细胞培养基领域的主要企业正透过技术深度、供应链整合以及超越单纯原料製备和供应的服务来脱颖而出。投资于应用科学、法规支援和现场技术支援的企业往往能与生物製药公司和契约製造建立长期伙伴关係。对製备平台（尤其是化学成分明确的培养基和无血清培养基解决方案）的策略性投资，能够打造兼具科研柔软性和临床稳健性的产品系列。

为供应商和最终用户提供切实可行的策略行动，以增强韧性、加速采用并透过综合服务和永续发展措施创造差异化价值。

产业领导企业应优先考虑一系列切实可行的倡议，以协调产品开发、供应链连续性和客户价值交付。首先，实现原材料和成品来源多元化，降低对特定地区的依赖，并透过标准化测试和协作验证来加快替代供应商的认证。其次，增加对化学成分明确和无血清配方产品的投入，并开发可靠的分析方案，以记录产品在相关细胞类型和製程窗口下的表现。这些措施既能确保研究的柔软性，又能确保临床级产品的稳定性。

采用透明且可重复的混合方法研究方法，结合一手访谈、实验室评估和供应链映射，以检验产业主题。

本分析采用定性和定量相结合的研究途径，以获得可靠且可重复的见解。主要调查包括对学术研究机构、受託研究机构和製造地的技术负责人进行结构化访谈，以收集关于配方性能、采购挑战和品质要求的第一手观点。补充的实验室评估和文献整合深化了对配方趋势和分析需求的深入技术解读，而供应链图谱则识别了关键采购环节和物流限制因素。

从整体观点培养基选择，将其视为一种策略能力，将配方科学、供应弹性和综合客户支援连结起来。

整体趋势清晰可见。细胞培养基正从单纯的通用试剂发展成为可重复科学研究和可扩展生物製造的策略基础。配方和分析技术的进步，以及供应链设计和服务交付的营运创新，提高了终端用户对供应商的期望。那些积极调整配方科学以符合监管要求、投资供应商多元化并提供一体化技术服务的企业，将更有能力降低风险并加快专案进度。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 细胞培养基市场：依产品类型划分

  • 含血清培养基
  • 无血清培养基

第九章 依细胞类型分類的细胞培养基市场

  • 哺乳动物细胞培养基
  • 微生物和昆虫细胞培养基
  • 植物细胞培养基

第十章 细胞培养基市场：依形式

  • 液体培养基
  • 粉状培养基

第十一章 细胞培养基市场：依应用领域划分

  • 生物加工和生产
  • 药物发现与测试
  • 研究与开发
  • 组织工程与再生医学

第十二章 细胞培养基市场：依最终用户划分

  • 学术研究机构
  • 合约研究机构
  • 製药和生物技术公司

第十三章 细胞培养基市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞培养基市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 细胞培养基市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国细胞培养基市场

第十七章：中国细胞培养基市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Avantor, Inc.
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Caisson Laboratories, Inc.
  • CellGenix GmbH
  • Corning Incorporated
  • Danaher Corporation
  • Eppendorf AG
  • FUJIFILM Corporation
  • HiMedia Laboratories Pvt Ltd.
  • Janssen Pharmaceuticals
  • Kohjin Bio Corporation
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Nucleus Biologics LLC
  • PeproTech, Inc.
  • PromoCell GmbH
  • Sartorius AG
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Wako Pure Chemical Industries, Ltd.
  • Wuxi AppTec Co., Ltd.
  • Xell AG
Product Code: MRR-433AB1DC28CE

The Cell Culture Media Market was valued at USD 1.79 billion in 2025 and is projected to grow to USD 2.00 billion in 2026, with a CAGR of 14.28%, reaching USD 4.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.79 billion
Estimated Year [2026] USD 2.00 billion
Forecast Year [2032] USD 4.58 billion
CAGR (%) 14.28%

A comprehensive primer on why cell culture media quality, supply continuity, and formulation innovation are decisive factors for modern life sciences operations

Cell culture media form the biochemical foundation on which a vast array of life sciences applications are built, enabling cell growth, differentiation, productivity, and viability across research and production environments. The composition, sterility, and performance characteristics of media directly influence experimental reproducibility, bioprocess yields, and the translational success of cell-based therapies. Given this centrality, organizations from academic labs to large biopharmaceutical manufacturers prioritize media selection, validation, and supply continuity as core operational imperatives.

As the life sciences ecosystem continues to diversify, the role of cell culture media has expanded beyond traditional laboratory support into mission-critical applications such as advanced biologics manufacturing, engineered tissues, and high-throughput screening platforms. This expansion amplifies requirements for consistency, regulatory alignment, and scalable supply chains. Consequently, media producers and end users are navigating a landscape that simultaneously demands technical innovation, stringent quality controls, and resilient procurement strategies. These pressures make clear that media strategy is both a scientific and a commercial priority for any organization aiming to deliver reliable biological outcomes.

How formulation advances, analytics, single use bioprocessing, and sustainability priorities are redefining supplier relationships and operational models in cell culture media

Recent years have witnessed several transformative shifts that are reshaping how organizations conceive, source, and deploy cell culture media across research and production workflows. Advances in formulation science have accelerated the adoption of chemically defined and serum-free options, which reduce variability and regulatory risk while enabling more predictable cell performance. Parallel improvements in analytic methods, including high-resolution metabolomics and real-time monitoring, have made it feasible to interrogate media performance at greater depth and to tune formulations to specific cell types and process stages.

Operationally, the rise of single-use technologies and modular bioprocess configurations has altered inventory and logistics models, encouraging just-in-time procurement and closer collaboration between media suppliers and end users. Meanwhile, digital tools for supply chain visibility and quality management are enabling faster issue resolution and more precise shelf-life assessments. Sustainability has also come to the fore, with companies exploring reduced packaging, recyclable materials, and lower carbon footprints for raw material sourcing. Taken together, these shifts are driving a transition from commoditized supply toward more integrated, service-oriented relationships between media manufacturers and their customers.

Navigating tariff-induced supply chain friction and strategic supply relocation considerations that influence procurement resilience and supplier qualification practices

Policy changes and tariff adjustments in major trade corridors have introduced measurable friction into global life sciences supply chains, prompting manufacturers and procurement teams to reassess sourcing strategies, cost structures, and inventory buffers. Tariff-driven increases in input costs have intensified scrutiny of raw material provenance and have motivated initiatives to qualify alternative suppliers closer to manufacturing footprints. In addition, companies have re-evaluated their contract terms and logistics arrangements to mitigate the higher landed costs associated with cross-border shipments.

Beyond direct cost implications, tariff pressures have catalyzed strategic shifts such as relocating critical production steps, diversifying vendor portfolios, and expanding local manufacturing capabilities. Organizations have also invested in enhanced traceability and supplier collaboration to reduce lead-time variability and to maintain regulatory compliance when moving production across jurisdictions. Importantly, these adaptations emphasize resilience: firms are balancing cost management with the need to preserve product quality, supply continuity, and the regulatory documentation required for biologics production and clinical supply chains.

An integrated segmentation perspective linking product formulation, cell host requirements, form factor, application use cases, and end user expectations to inform strategic decisions

Effective segmentation provides the analytical lens needed to translate formulation science and operational requirements into procurement and development decisions. Based on Product Type, market is studied across Serum-Containing Media and Serum-Free Media, a distinction that drives considerations around batch-to-batch variability, regulatory documentation, and the suitability of the media for clinical applications. Based on Cell Type, market is studied across Mammalian Cell Culture Media, Microbial And Insect Cell Culture Media, and Plant Cell Culture Media, reflecting the diverse biochemical needs and process constraints of different host systems. Based on Form, market is studied across Liquid Media and Powdered Media, which influences storage, transport, and onsite preparation practices and can affect turnaround times for process scaling. Based on Application, market is studied across Bioprocessing And Production, Drug Discovery And Testing, Research And Development, and Tissue Engineering And Regenerative Medicine, highlighting how performance requirements shift from high-throughput flexibility to clinical-grade reproducibility. Based on End User, market is studied across Academic And Research Institutes, Contract Research Organizations, and Pharmaceutical And Biotechnology Companies, underscoring differences in purchasing power, quality systems, and expectations for technical support and customization.

Interpreting these segmentation axes together enables a more nuanced appreciation of buyer behavior and technical prioritization. For instance, pharmaceutical and biotechnology companies typically place premium value on chemically defined, clinical-grade serum-free media for mammalian cell culture workflows, while academic and research institutes may favor flexible, convenient liquid formulations for exploratory work. Contract research organizations frequently require a hybrid approach that balances throughput, cost, and documented reproducibility to support client programs. Similarly, applications such as tissue engineering impose unique demands for scaffold compatibility and differentiation support that shape formulation choices. Understanding these intersecting segmentation dimensions supports more targeted product development, regulatory planning, and customer engagement strategies.

How regional innovation hubs, regulatory landscapes, and manufacturing footprints shape procurement approaches and supplier engagement across global life sciences regions

Regional dynamics shape the operational priorities and regulatory expectations that influence cell culture media procurement and development. In the Americas, a dense concentration of academic institutions, innovative biotechs, and large contract development and manufacturing organizations creates strong demand for high-performance, regulatory-ready media and close technical support. The Americas region also features advanced logistics networks that enable rapid distribution but also places a premium on compliance documentation and quality management systems.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks, reimbursement mechanisms, and academic-commercial collaborations vary by jurisdiction. This region often emphasizes stringent quality standards and sustainability commitments, prompting manufacturers to adapt packaging, sourcing, and carbon management practices. Meanwhile, Asia-Pacific combines rapidly expanding biopharma manufacturing capacity with a strong emphasis on cost-competitive solutions and local supplier development, leading to investments in regional production sites and partnerships. Each region's regulatory environment, infrastructure maturity, and innovation ecosystem inform different go-to-market approaches, partnership models, and product support strategies for suppliers and end users alike.

Insights into how scientific specialization, service-oriented models, and operational reliability create competitive advantage and foster long-term partnerships in media supply

Leading companies in the cell culture media domain are differentiating through technical depth, supply chain integration, and services that extend beyond raw formulation supply. Firms that invest in application science, regulatory support, and on-site technical assistance tend to secure longer-term partnerships with biopharma and contract manufacturing organizations. Strategic investments in formulation platforms, especially for chemically defined and serum-free solutions, enable product portfolios that address both research flexibility and clinical robustness.

Competitive dynamics also reward specialization: companies offering tailored media for niche cell types or high-value applications such as induced pluripotent stem cell expansion and regenerative medicine carve out defensible positions. Collaboration between suppliers and end users on joint development, case studies, and co-validation programs accelerates adoption while distributing technical risk. Finally, operational excellence in quality systems, batch traceability, and logistics reliability remains a critical differentiator, particularly for customers managing clinical manufacturing and regulatory inspections. Firms that combine scientific leadership with dependable supply and responsive technical support are positioned to capture strategic relationships across the value chain.

Practical strategic actions for suppliers and end users to strengthen resilience, accelerate adoption, and create differentiated value through integrated service and sustainability initiatives

Industry leaders should prioritize a set of pragmatic actions to align product development, supply continuity, and customer value delivery. First, diversify raw material and finished goods sourcing to reduce dependency on single geographies while accelerating qualification of alternative suppliers through standardized testing and joint validation. Second, expand investments in chemically defined and serum-free formulations alongside robust analytical packages that document performance across relevant cell types and process windows. This combination will support both research flexibility and clinical-grade consistency.

Third, enhance supply chain visibility through digital tools that track lot performance, shelf life, and logistics movements to preempt disruptions and to facilitate rapid corrective actions. Fourth, develop integrated service offerings that combine media supply with technical training, on-site troubleshooting, and co-development partnerships, thereby increasing customer switching costs and demonstrating value beyond product price. Fifth, embed sustainability targets into packaging, sourcing, and manufacturing operations to meet growing buyer expectations and to reduce lifecycle impacts. Collectively, these actions will strengthen resilience, improve customer retention, and create differentiated value propositions in an increasingly sophisticated market.

A transparent and reproducible mixed-methods research approach combining primary interviews, laboratory assessment, and supply chain mapping to validate industry themes

The research approach underpinning this analysis combined qualitative and quantitative methods to achieve robust, reproducible insights. Primary engagement included structured interviews with technical leaders across academic labs, contract research organizations, and manufacturing sites to capture first-hand perspectives on formulation performance, procurement challenges, and quality requirements. Complementary laboratory assessments and literature synthesis informed technical interpretation of formulation trends and analytical needs, while supply chain mapping exercises identified key sourcing nodes and logistical constraints.

Data triangulation across these inputs enabled the validation of recurring themes and the identification of emergent patterns, and a rigorous review process with subject-matter experts ensured conceptual accuracy and relevance. Attention to reproducibility guided documentation standards, and sensitivity checks were performed to account for regional regulatory differences and product-use cases. The methodology emphasizes transparency, traceability, and applicability to support actionable decision-making without relying on single-source assumptions.

Summative perspectives on treating media selection as a strategic capability that links formulation science, supply resilience, and integrated customer support

The cumulative picture is clear: cell culture media are evolving from commodity reagents into strategic enablers of reproducible science and scalable biomanufacturing. Technical advances in formulation and analytics, coupled with operational innovations in supply chain design and service delivery, are raising the bar for what end users expect from suppliers. Organizations that proactively align formulation science with regulatory needs, invest in supplier diversification, and offer integrated technical services will be better positioned to mitigate risk and accelerate project timelines.

As the ecosystem matures, the most successful players will be those that combine scientific rigor with operational excellence and customer-centric support models. This synthesis will drive greater predictability in experimental outcomes, smoother translation to clinical and commercial stages, and stronger collaborative partnerships across the life sciences value chain. The strategic imperative is to treat media selection and supply not as a transactional procurement decision but as a core component of scientific and operational strategy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Culture Media Market, by Product Type

  • 8.1. Serum-Containing Media
  • 8.2. Serum-Free Media

9. Cell Culture Media Market, by Cell Type

  • 9.1. Mammalian Cell Culture Media
  • 9.2. Microbial And Insect Cell Culture Media
  • 9.3. Plant Cell Culture Media

10. Cell Culture Media Market, by Form

  • 10.1. Liquid Media
  • 10.2. Powdered Media

11. Cell Culture Media Market, by Application

  • 11.1. Bioprocessing And Production
  • 11.2. Drug Discovery And Testing
  • 11.3. Research And Development
  • 11.4. Tissue Engineering And Regenerative Medicine

12. Cell Culture Media Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical And Biotechnology Companies

13. Cell Culture Media Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Culture Media Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Culture Media Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell Culture Media Market

17. China Cell Culture Media Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Avantor, Inc.
  • 18.6. Becton, Dickinson and Company
  • 18.7. Bio-Techne Corporation
  • 18.8. Caisson Laboratories, Inc.
  • 18.9. CellGenix GmbH
  • 18.10. Corning Incorporated
  • 18.11. Danaher Corporation
  • 18.12. Eppendorf AG
  • 18.13. FUJIFILM Corporation
  • 18.14. HiMedia Laboratories Pvt Ltd.
  • 18.15. Janssen Pharmaceuticals
  • 18.16. Kohjin Bio Corporation
  • 18.17. Lonza Group AG
  • 18.18. Merck KGaA
  • 18.19. Miltenyi Biotec B.V. & Co. KG
  • 18.20. Nucleus Biologics LLC
  • 18.21. PeproTech, Inc.
  • 18.22. PromoCell GmbH
  • 18.23. Sartorius AG
  • 18.24. STEMCELL Technologies Inc.
  • 18.25. Takara Bio Inc.
  • 18.26. Thermo Fisher Scientific Inc.
  • 18.27. Wako Pure Chemical Industries, Ltd.
  • 18.28. Wuxi AppTec Co., Ltd.
  • 18.29. Xell AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL CULTURE MEDIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL CULTURE MEDIA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL CULTURE MEDIA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL CULTURE MEDIA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL CULTURE MEDIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY SERUM-CONTAINING MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY SERUM-CONTAINING MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY SERUM-CONTAINING MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY MAMMALIAN CELL CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY MAMMALIAN CELL CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY MAMMALIAN CELL CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY MICROBIAL AND INSECT CELL CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY MICROBIAL AND INSECT CELL CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY MICROBIAL AND INSECT CELL CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PLANT CELL CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PLANT CELL CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PLANT CELL CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY LIQUID MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY LIQUID MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY LIQUID MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY POWDERED MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY POWDERED MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY POWDERED MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY BIOPROCESSING AND PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY BIOPROCESSING AND PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY BIOPROCESSING AND PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY DRUG DISCOVERY AND TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY DRUG DISCOVERY AND TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY DRUG DISCOVERY AND TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY TISSUE ENGINEERING AND REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY TISSUE ENGINEERING AND REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY TISSUE ENGINEERING AND REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS CELL CULTURE MEDIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA CELL CULTURE MEDIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. GCC CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 109. GCC CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 127. G7 CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NATO CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 133. NATO CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA CELL CULTURE MEDIA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA CELL CULTURE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA CELL CULTURE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA CELL CULTURE MEDIA MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA CELL CULTURE MEDIA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA CELL CULTURE MEDIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)